ICMJE DISCLOSURE FORM

Date: May. 4 th , 2023	
Your Name: Wei Meng	
Manuscript Title: A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and imm	nuni
in clear cell renal cell carcinoma	
Manuscript number (if known): TCR-23-227	
to the interest of terrorises were only one to displace all relationships for the latest to describe the description of the control of the co	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	- So months
-	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
3	Noyanies of ficerises		
4	Consulting foor	X None	
4	Consulting fees	X_None	
\vdash			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
-	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or	110110	
	Advisory Board		
10	Leadership or fiduciary role	X None	
20	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
	Stock of Stock options		
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
13	financial interests		
	imancial interests		

Please summarize the above conflict of interest in the following box:

ſ	None.
l	
l	
l	

Please place an "X" next to the following statement to indicate your agreement:

ICMJE DISCLOSURE FORM

Date: May. 4th, 2023

Your Name:Bo Chen

Manuscript Title: A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma

Manuscript number (if known): TCR-23-227

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
\perp			
5	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	X None	
0	pending	_ANone	
	B-all-sals-sals-sals-sals-sals-sals-sals	N. N	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non- financial interests	XNone	

Please place an "X" next to the following statement to indicate your agreement:

Please summarize the above conflict of interest in the following box:

None.

		ICMJE DISC	LOSURE FORM
You Ma in a	te: <u>May. 4th, 2023</u> ur Name: <u>Zhaosheng Jiang</u> unuscript Title: <u>A compreher</u> clear cell renal cell carcinom unuscript number (if known)	a	a promising biomarker for diagnosis, prognosis, and immun
The ma	ated to the content of your rites whose interests may be transparency and does not a ationship/activity/interest, e following questions apply unuscript only. e author's relationships/act the epidemiology of hypertedication, even if that medic	manuscript. "Related" me e affected by the content c encessarily indicate a bias. it is preferable that you do to the author's relationshi ivities/interests should be ension, you should declare ation is not mentioned in a prort for the work reporte s the past 36 months.	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains <u>all relationships with manufacturers of antihypertensive</u>
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initia _X_None	planning of the work
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past	36 months
3		X None	
3	Royalties or licenses	X_None	
4	Royalties or licenses Consulting fees	X_None	
	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or		
4	Consulting fees Payment or honoraria for lectures, presentations, speakers bureaus,	_X_None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending	XNone	
5 6 7	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or	_X_None _X_None _X_None	
5 6 7 8 9	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNoneXNoneXNoneXNoneXNoneXNone	
5 6 7 7 8 8 9	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options	X_NoneX_NoneX_NoneX_NoneX_NoneX_None	
5 6 7 8 9	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNoneXNoneXNoneXNoneXNoneXNone	

Please summarize the above conflict of interest in the following box:

None.			

Please place an "X" next to the following statement to indicate your agreement:

ICMJE DISCLOSURE FORM
Date: May. 4th, 2023
Your Name:Bo Cai
Manuscript Title: A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunit
in clear cell renal cell carcinoma
Manuscript number (if known): TCR-23-227
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

The following questions apply to the author's relationships/activities/interests as they relate to the $\underline{\text{current}}$

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entitles with whom you have this relationship or indicate none (add rows as needed) Name all entitles with whom you have this relationship or indicate none (add rows as needed) Name and the provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. No time limit for this			Name of antistancist	6
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. 2 Grants or contracts from any entity (if not indicated in item #1 above). 3 Royalties or licenses 4 Consulting fees X_None 5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None			relationship or indicate none (add rows as needed)	institution)
manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. 2 Grants or contracts from any entity (if not indicated in item #1 above). 3 Royalties or licenses			Time frame: Since the initia	al planning of the work
2 Grants or contracts from any entity (if not indicated in item #1 above). 3 Royalties or licenses **X_None** **A Consulting fees **X_None** **A None** **A	1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	X_None	
2 Grants or contracts from any entity (if not indicated in item #1 above). 3 Royalties or licenses **X_None** **A Consulting fees **X_None** **A None** **A				
any entity (if not indicated in item #1 above). Royalties or licenses X_None X_None Consulting fees X_None				t 36 months
4 Consulting fees	2	any entity (if not indicated	X_None	
5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert	3	Royalties or licenses	XNone	
5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert				
5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert				
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical writing, gifts or other services Receipt of equipment, materials, drugs, medical writing, gifts or other services Table Value of the value of the properties of the value of the properties of the value	4	Consulting fees	X_None	
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical writing, gifts or other services Receipt of equipment, materials, drugs, medical writing, gifts or other services Table Value of the value of the properties of the value of the properties of the value				
lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical writing, gifts or other services Receipt of equipment, materials, drugs, medical writing, gifts or other services Table Value of the value of the properties of the value of the properties of the value				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X None	5	Payment or honoraria for	XNone	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X None		lectures, presentations,		
educational events Payment for expert testimony Support for attending meetings and/or travel Participation on a Data Safety Monitoring Board or Advisory Board or In other board, society, committee or advocacy group, paid or unpaid Pecceipt of equipment, materials, drugs, medical writing, gifts or other services Name of the payment				
6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X_None				
testimony Support for attending meetings and/or travel				
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board or In Use of the board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X_None	6		XNone	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X None X None		testimony		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X None X None				
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None	7		XNone	
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None				
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X_None	8	Patents planned, issued or	_XNone	
Safety Monitoring Board or Advisory Board or Advisory Board or Advisory Board or Discourage of Safety Monitoring Board or Advisory Board or Safety Committee or advocacy group, paid or unpaid or un		pending		
Safety Monitoring Board or Advisory Board or Advisory Board or Advisory Board or Discourage of Safety Monitoring Board or Advisory Board or Safety Committee or advocacy group, paid or unpaid or un				
Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Z_None Receipt of equipment, materials, drugs, medical writing, gifts or other services Tother financial or non- Z_None	9		XNone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X_None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None 22 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X_None				
committee or advocacy group, paid or unpaid 11 Stock or stock options	10		xNone	
group, paid or unpaid 11 Stock or stock options X_None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or nonX_None	11	group, paid or unpaid	V None	
materials, drugs, medical writing, gifts or other services 13 Other financial or nonX_None	11	Stock of stock options	^_None	
materials, drugs, medical writing, gifts or other services 13 Other financial or nonX_None				
materials, drugs, medical writing, gifts or other services 13 Other financial or nonX_None	12	Pecaint of equipment	V None	
writing, gifts or other services 13 Other financial or nonX_None	12		^_None	
13 Other financial or nonX_None				
	13	00111000	X None	

Please summarize the above conflict of interest in the following box:

None.			

Please place an "X" next to the following statement to indicate your agreement:

		ICMJE DISCI	LOSURE FORM	
Yo Ma in	Date: <u>May. 4th, 2023</u> Your Name: <u>Limin Ma</u> Manuscript Title: <u>A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma Manuscript number (if known): <u>TCR-23-227</u></u>			
rei pa to	ated to the content of your i	manuscript. "Related" mea affected by the content of necessarily indicate a bias.	relationships/activities/interests listed below that ar ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmer If you are in doubt about whether to list a so.	
	The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .			
to		nsion, you should declare	<u>defined broadly</u> . For example, if your manuscript pert all relationships with manufacturers of antihypertens the manuscript.	
	item #1 below, report all sup e time frame for disclosure is		d in this manuscript without time limit. For all other i	tems,
		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)	

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: pas	t 26 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	30 months
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

Please summarize the above conflict of interest in the following box:

	None.
ı	
ı	

Please place an "X" next to the following statement to indicate your agreement:

ICMJE DISCLOSURE FORM
Date: May. 4 th , 2023 Your Name: Yangbo Guan Manuscript Title: A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma Manuscript number (if known): TCR-23-227
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> .

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your institution)
		relationship or indicate none (add rows as needed)	institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	X_None	

Please summarize the above conflict of interest in the following box:

	None.
l	
ı	

Please place an "X" next to the following statement to indicate your agreement: